Immunomedics submits additional CEA-Scan data
This article was originally published in Clinica
Executive Summary
Immunomedics (US) claims that its CEA-Scan colorectal imaging agent provides clinically useful information for pre-surgical evaluation of recurrent cancer patients. Results were derived from Phase III trials in response to the US FDA's request for additional information after the agency found the agent not approvable last year (see Clinica No 605, p 26). Immunomedics has submitted the additional data to the FDA.